Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 - Perez, E A; Romond, E H; Suman, V J (J Clin Oncol, 2011)